National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
JAMA Netw Open. 2020 May 1;3(5):e204514. doi: 10.1001/jamanetworkopen.2020.4514.
Although opioids can be effective medications in certain situations, they are associated with harms, including opioid use disorder and overdose. Studies have revealed unexplained prescribing variation and prescribing mismatched with patient-reported pain for many indications.
To summarize opioid prescribing frequency, dosages, and durations, stratified across numerous painful medical indications.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cross-sectional analysis of 2017 US administrative claims data among outpatient clinical settings, including postsurgical discharge. Participants had any of 41 different indications associated with nonsurgical acute or chronic pain or postsurgical pain or pain associated with sickle cell disease or active cancer and were enrolled in either private insurance (including Medicare Advantage) in the OptumLabs Data Warehouse data set (n = 18 016 259) or Medicaid in the IBM MarketScan Multi-State Medicaid Database (n = 11 453 392). OptumLabs data were analyzed from October 2018 to March 2019; MarketScan data were analyzed from January to April 2019.
Nonsurgical acute or chronic pain or postsurgical pain; pain related to sickle cell disease or active cancer.
Indication-specific opioid prescribing rates; days' supply per prescription; daily opioid dosage in morphine milligram equivalents; and for chronic pain indications, the number of opioid prescriptions.
During the study period, of 18 016 259 eligible patients with private insurance, the mean (95% CI) age was 42.7 (42.7-42.7) years, and 50.3% were female; of 11 453 392 eligible Medicaid enrollees, the mean (95% CI) age was 20.4 (20.4-20.4) years, and 56.1% were female. A pain-related indication under study occurred in at least 1 visit among 6 380 694 patients with private insurance (35.4%) and 3 169 831 Medicaid enrollees (27.7%); 2 270 596 (35.6% of 6 380 694) privately insured patients and 1 126 508 (35.5% of 3 169 831) Medicaid enrollees had 1 or more opioid prescriptions. Nonsurgical acute pain opioid prescribing rates were lowest for acute migraines (privately insured, 4.6% of visits; Medicaid, 6.6%) and highest for rib fractures (privately insured, 44.8% of visits; Medicaid, 56.3%), with variable days' supply but similar daily dosage across most indications. Opioid prescribing for a given chronic pain indication varied depending on a patient's opioid use history. Days' supply for postoperative prescriptions was longest for combined spinal decompression and fusion (privately insured, 9.5 days [95% CI, 9.4-9.7 days]) or spinal fusion (Medicaid, 9.1 days [95% CI, 8.9-9.2 days]) and was shortest for vaginal delivery (privately insured, 4.1 days [95% CI, 4.1-4.1 days] vs Medicaid, 4.2 days [95% CI, 4.2-4.2 days]).
Indication-specific opioid prescribing rates were not always aligned with existing guidelines. Potential inconsistencies between prescribing practice and clinical recommendations, such as for acute and chronic back pain, highlight opportunities to enhance pain management and patient safety.
虽然阿片类药物在某些情况下可能是有效的药物,但它们与危害有关,包括阿片类药物使用障碍和过量。研究表明,许多适应症的处方存在无法解释的差异,且与患者报告的疼痛不匹配。
总结各种疼痛医疗适应症的阿片类药物处方频率、剂量和持续时间。
设计、设置和参与者:对 2017 年美国门诊临床环境(包括手术后出院)的 2017 年美国行政索赔数据进行回顾性横断面分析。参与者有 41 种不同的适应症,与非手术急性或慢性疼痛、手术后疼痛、镰状细胞病或活动性癌症相关的疼痛或疼痛有关,并参加了 OptumLabs 数据仓库(n=18,016,259)或 IBM MarketScan 多州医疗补助数据库(n=11,453,392)中的私人保险(包括医疗保险优势计划)或医疗补助。OptumLabs 数据于 2018 年 10 月至 2019 年 3 月进行分析;MarketScan 数据于 2019 年 1 月至 4 月进行分析。
非手术急性或慢性疼痛、手术后疼痛;与镰状细胞病或活动性癌症相关的疼痛。
特定适应症的阿片类药物处方率;每处方的供应天数;吗啡毫克当量的每日阿片类药物剂量;以及慢性疼痛适应症的阿片类药物处方数量。
在研究期间,在 18,016,259 名有私人保险的合格患者中,平均(95%CI)年龄为 42.7(42.7-42.7)岁,50.3%为女性;在 11,453,392 名有医疗补助资格的患者中,平均(95%CI)年龄为 20.4(20.4-20.4)岁,56.1%为女性。在有私人保险的 6,380,694 名患者(35.4%)和 3,169,831 名医疗补助患者(27.7%)中,至少有 1 次就诊出现了与疼痛相关的适应症;2,270,596 名(6,380,694 名患者的 35.6%)有私人保险的患者和 1,126,508 名(3,169,831 名医疗补助患者的 35.5%)有医疗补助的患者有 1 次或多次阿片类药物处方。非手术急性疼痛的阿片类药物处方率最低的是急性偏头痛(有私人保险的患者,就诊的 4.6%;有医疗补助的患者,就诊的 6.6%),最高的是肋骨骨折(有私人保险的患者,就诊的 44.8%;有医疗补助的患者,就诊的 56.3%),大多数适应症的供应天数不同,但每日剂量相似。特定慢性疼痛适应症的阿片类药物处方取决于患者的阿片类药物使用史。术后处方的供应天数最长的是联合脊柱减压融合术(有私人保险的患者,9.5 天[95%CI,9.4-9.7 天]或脊柱融合术(有医疗补助的患者,9.1 天[95%CI,8.9-9.2 天]),最短的是阴道分娩(有私人保险的患者,4.1 天[95%CI,4.1-4.1 天]与有医疗补助的患者,4.2 天[95%CI,4.2-4.2 天])。
特定适应症的阿片类药物处方率并不总是与现有指南一致。急性和慢性背痛等适应症的处方实践与临床建议之间存在潜在的不一致,这为加强疼痛管理和患者安全提供了机会。